Vaccine Toxicity Studies Could Use Earlier FDA Input, Reviewer Suggests
FDA may need to develop a mechanism for providing advice to sponsors on preclinical toxicity studies prior to the pre-IND meeting, FDA Office of Vaccines Scientific Reviewer Marion Gruber, PhD, suggested
You may also be interested in...
A workshop by FDA's Center for Biologics Evaluation & Research on preventative vaccine development Dec. 2-3 will consider the maximum dose for animal toxicology studies
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials